Clinical Trials Directory

Trials / Completed

CompletedNCT02621060

Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance

Effect of the Administration of Chlorogenic Acid on Glucemic Control, Insulin Secretion and Insulin Sensitivity in Patients With Impaired Glucose Tolerance

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
30 (actual)
Sponsor
University of Guadalajara · Academic / Other
Sex
All
Age
30 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Chlorogenic acid has demonstrated promising effects in the treatment of glycemic control, obesity, dyslipidemia, insulin secretion, among others. The above mentioned findings show that Chlorogenic acid has an excellent potential for the control of glucose as well as insulin secretion and insulin sensitivity.

Detailed description

A randomized, double-blind, placebo-controlled clinical trial was carried out in 30 patients with a diagnosis of impaired glucose tolerance in accordance with the American Diabetes Association criteria. The patients received 400 mg capsules of Chlorogenic acid or placebo, three times daily 1/ 2 hour before meals for 90 days. Before and after intervention the investigators evaluated: 2 hours plasma glucose, glycated hemoglobin (A1C), triglycerides, high-density lipoprotein, fasting glucose and blood pressure body weight, body mass index, waist circumference, total cholesterol, low-density lipoprotein, very-low-density lipoprotein, creatinine, aspartate transaminase and alanine transaminase. Were calculated: Areas under the curve of glucose and insulin were calculated with de Trapezoidal formula. Total insulin secretion was evaluated with the Insulinogenic index and the insulin sensitivity was estimated using the Matsuda index.

Conditions

Interventions

TypeNameDescription
DRUGPlaceboPlacebo: 1200 mg per day for three months
DRUGChlorogenic acidChologenic acid: 1200 mg per day for three months

Timeline

Start date
2015-09-01
Primary completion
2016-01-01
Completion
2016-02-01
First posted
2015-12-03
Last updated
2019-08-02
Results posted
2019-08-02

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT02621060. Inclusion in this directory is not an endorsement.